



# LUND UNIVERSITY

## **Ethnicity is an independent risk indicator when estimating diabetes risk with FINDRISC scores: A cross sectional study comparing immigrants from the Middle East and native Swedes.**

Bennet, Louise; Groop, Leif; Lindblad, Ulf; Agardh, Carl-David; Franks, Paul

*Published in:*  
Primary Care Diabetes

*DOI:*  
[10.1016/j.pcd.2014.01.002](https://doi.org/10.1016/j.pcd.2014.01.002)

2014

[Link to publication](#)

### *Citation for published version (APA):*

Bennet, L., Groop, L., Lindblad, U., Agardh, C.-D., & Franks, P. (2014). Ethnicity is an independent risk indicator when estimating diabetes risk with FINDRISC scores: A cross sectional study comparing immigrants from the Middle East and native Swedes. *Primary Care Diabetes*, 8(3), 231-238.  
<https://doi.org/10.1016/j.pcd.2014.01.002>

*Total number of authors:*  
5

### **General rights**

Unless other specific re-use rights are stated the following general rights apply:  
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

Read more about Creative commons licenses: <https://creativecommons.org/licenses/>

### **Take down policy**

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

LUND UNIVERSITY

PO Box 117  
221 00 Lund  
+46 46-222 00 00



Ethnicity is an independent risk indicator when estimating diabetes risk with FINDRISC scores; A cross sectional study comparing immigrants from the Middle East and native Swedes

L. Bennet<sup>1</sup>, L. Groop<sup>1,2</sup>, U. Lindblad<sup>4</sup>, C-D. Agardh<sup>1\*</sup>, P.W. Franks<sup>1</sup>,

<sup>1</sup>Department of Clinical Sciences, Lund University, Skåne University Hospital, Sweden

<sup>2</sup>Department of Diabetes and Endocrinology/Lund Diabetes Centre, Skåne University Hospital, Malmö, Sweden.

<sup>3</sup> Department of Primary Health Care, Institute of Medicine, University of Gothenburg, Sweden

\* Deceased

Word count: Abstract 200; Manuscript 3088

Tables: 2      Figures: 2

Corresponding author:

Louise Bennet

Center for Primary Health Care Research, Clinical Research Center, Entrance 72, building 60,  
floor 12

Jan Waldenströms gata 37, Skåne University Hospital  
205 02 Malmö, Sweden

Phone: +46 40 391388, Fax: +46 40 391370

e-mail: [Louise.Bennet@med.lu.se](mailto:Louise.Bennet@med.lu.se)

Funding: This study was funded by grants from Lund University (ALF grant Skane 20101641, 20101837, 162641 and 56891), Strategical Research Grants M 2011/255, Region Skåne (121811, 226661 and 279571), The Swedish Society of Medicine (SLS 97081,176831 and 329581) the Crafoord Foundation (20110719) and the Swedish Research Council (Linné grant to LUDC, 349-2008-6589, Exodiab, 2009-1039 and ANDIS 825-2010-5983)

Conflict of interest:

No potential conflict of interest relevant to this article was reported.

**Abstract:**

Aims: This study sought to compare type 2 diabetes (T2D) risk indicators in Iraqi immigrants with those in ethnic Swedes living in southern Sweden.

Methods: Population-based, cross-sectional cohort study of men and women, aged 30–75 years, born in Iraq or Sweden conducted in 2010–2012 in Malmö, Sweden. A 75 g oral glucose tolerance test was performed and sociodemographic and lifestyle data were collected. T2D risk was assessed by the Finnish Diabetes Risk Score (FINDRISC).

Results: In Iraqi versus Swedish participants, T2D was twice as prevalent (11.6 vs. 5.8%,  $p<0.001$ ). A large proportion of the excess T2D risk was attributable to larger waist circumference and first-degree family history of diabetes. However, Iraqi ethnicity was a risk factor for T2D independently of other FINDRISC factors (odds ratio 2.5, 95% CI 1.6–3.9). The FINDRISC algorithm predicted that more Iraqis than Swedes (16.2 vs. 12.3%,  $p<0.001$ ) will develop T2D within the next decade. The total annual costs for excess T2D risk in Iraqis are estimated to exceed 2.3 million euros (2005), not accounting for worse quality of life.

Conclusions:

Our study suggests that Middle Eastern ethnicity should be considered an independent risk indicator for diabetes. Accordingly, the implementation of culturally tailored prevention programs may be warranted.

Keywords: type 2 diabetes, incidence, prevalence, Middle East, FINDRISC

## Background

Type 2 diabetes (T2D) is one of the strongest risk factors for cardiovascular disease and premature death [1]. The prevalence of T2D is continuously increasing worldwide, and it is estimated that by 2025 that 15% of the global population will be affected by T2D, impaired fasting glucose (IFG) or impaired glucose tolerance (IGT) [2].

Of the five countries with the highest diabetes prevalence, four are located in the Middle East, where overall prevalence rates vary between 7 and 20% [3, 4]. Migration and urbanization are known risk factors for T2D [5] and epidemiological studies have shown that immigrants from the Middle East have a high prevalence of T2D, which is partly thought to be a consequence of obesity (body mass index,  $\text{BMI} \geq 30 \text{ kg/m}^2$ ), which is highly prevalent in non-European immigrants [6]. Considering the risk of reduced quality of life [7] and of diabetic complications and early death, determining the metabolic, lifestyle and heritable risk factors that underlie the high diabetes prevalence in immigrant populations from the Middle East is of high priority.

The total annual diabetes-related costs for healthcare, productivity loss, lost life-years and lost productivity years (as a result of mortality or permanent disability) was roughly 920 million euros (mEUR) in 2005, more than twice the expenditure in 1987 (439 mEUR), owing largely to a sharp increase in the disease's prevalence [8]. Thus, there are substantial health incentives as well as economic incentives to detect and prevent from the development of diabetes, especially in high-risk populations. Moreover, as highlighted in a recent systematic review [9], there is a relative dearth of such studies, particularly in immigrant communities.

The purpose of the current study was to determine and compare the prevalence of T2D and the frequency of intermediate risk factors for T2D in Middle Eastern immigrants to Sweden and ethnic Swedes living within the same region of southern Sweden. This study also sought to estimate and compare the future burden and incidence of diabetes in these populations using the

Finnish Diabetes Risk Score, FINDRISC [10], which was developed as a population screening tool for Nordic populations [10].

## **Methods and procedures**

In the MEDIM study (the impact of Migration and Ethnicity on Diabetes In Malmö) citizens of Malmö born in Iraq or Sweden 30 to 75 years of age were randomly selected from the census register and invited by mail and phone to participate in this population-based survey. We aimed to recruit Iraqi and Swedish groups matched for sex and 10-year age distributions (2:1 matching). People with type 1 diabetes, severe physical or mental illness or disabilities were not included in the study. Participants included second-generation immigrants born in Sweden. All participants fulfilling the inclusion criteria were enrolled consecutively in the survey as they accepted to participate and no individuals were excluded due to inconsistent matching with age group.

To minimize cohort effects and assessment biases, examinations were conducted within a relatively short timeframe (February 1, 2010 through December 31, 2012). Figure 1 shows a flow chart describing the recruitment of MEDIM participants.

### *Power and sample size calculation*

Power calculation was based on estimations on differences in T2D in an adult Swedish and Iraqi population. We estimated that the T2D prevalence would be 7% in a Middle Eastern population and 4% in native Swedes [5]. With  $\alpha=0.05$  (two sided test) and a power of 80% we would detect a significant difference in T2D prevalence with a sample size of 1400 participants born in Iraq and 1400 born in Sweden. However, the study was stopped in advance since T2D prevalence was higher than estimated amongst Iraqis; with these differences in prevalence, the sample size yielded an estimated power of 99% to determine that this difference was statistically significant.



### *Ethical considerations*

All participants provided written informed consent and the Ethics Committee at Lund University approved the study (No. 2009/36 & 2010/561). This investigation conforms to the principles outlined in the Declaration of Helsinki [11].

### *Physical examination*

Trained Swedish and Arabic speaking research nurses conducted standard physical examinations. Assessment of standard physical examinations and clinical variables such as blood pressure, height, weight, body mass index (BMI) and waist circumference was performed as described previously [12].

### *Blood samples and oral glucose tolerance test (OGTT)*

Participants were instructed not to eat or drink anything but water or consume tobacco later than 10 pm the day before the OGTT and to bring a record of their current medications. The following morning a 75g oral glucose tolerance test (OGTT) was performed. Blood samples were collected prior to the glucose load and at 30, 60, 90 and 120 minutes; glucose was analyzed continuously on fresh plasma from venous whole blood immediately after sampling using a photometer (HemoCue AB, Ängelholm, Sweden) as described previously [12]. New cases of diabetes were confirmed by fasting plasma glucose level of  $\geq 7.0$  mmol/L and/or by a 2-h plasma glucose level of  $\geq 11.1$  mmol/L. Two pathological values were needed for diagnosis [13] and if only one glucose value was indicative of diabetes, the OGTT was repeated another day with the same fasting procedures. Participants stating they had existing diabetes, were considered as previously

diagnosed diabetes cases if they were on medication with oral hypoglycaemic agents and/or insulin or if they had fasting glucose  $\geq 7.0$  mmol/l. Participants with previously known diabetes did not undergo an OGTT.

Impaired fasting glucose (IFG) was defined as a fasting plasma glucose level of  $\geq 6.1$  mmol/L and  $< 7.0$  mmol/L and a 2-h plasma glucose level of  $< 7.8$  mmol/L [13]. Impaired glucose tolerance (IGT) was defined as a fasting plasma glucose level of  $< 6.1$  mmol/L and a 2-h plasma glucose level of  $\geq 7.8$  mmol/L and  $< 11.1$  mmol/L [13] and impaired glucose regulation (IGR) was defined as IFG in combination with IGT.

### *Questionnaires*

Information on lifestyle habits, family history of diabetes, previous diagnosis of diabetes, present medication and family history of diabetes (in biological parents and/or siblings) and sociodemography was collected through interviews conducted by Arabic and Swedish speaking nurses using structured questionnaires in Swedish and Arabic as described previously [12]. All questionnaires were translated and back-translated by two independent professional translators with Arabic as their native language [12].

### *The Finnish Diabetes Risk Score, FINDRISC*

FINDRISC estimates the risk of developing diabetes within the next 10 years [10]. The scores are based on age, anthropometrical measures such as BMI and waist circumference, family history of diabetes in second- or first degree biological relatives, lifestyle factors such as physical activity and intake of fruit and vegetables, history of gestational diabetes and medication for hypertension.

Diabetes risk was assessed according to FINDRISC scores

([http://www.diabetes.fi/files/1100/Type2diabetesRiskTest\\_.jpg](http://www.diabetes.fi/files/1100/Type2diabetesRiskTest_.jpg)). Risk estimates for diabetes within the next decade are according to FINDRISC: low risk <7 points (p), 1 in 100 develop diabetes; slightly elevated risk 7 to 11p, 1 in 25 develop diabetes; moderate risk 12 to 14p, 1 in 6 develop diabetes; high risk 15 to 20p, 1 in 3 develop diabetes and very high risk  $\geq 21$  p, 1 in 2 develop diabetes within the next decade [10]. Participants with IGT or IGR were also considered being at very high risk [14, 15].

The following risk factors were assessed in the FINDRISC form:

*Age:* <45 years (0p); 45 to 54 years (2p); 55 to 64 years (3p); >64 years (4p).

*BMI:* <25 kg/m<sup>2</sup> (0p), 25 to 30 kg/m<sup>2</sup> (1p); >30 kg/m<sup>2</sup> (3p);

*Waist circumference:* men<94 cm, women<80 cm (0p); men 94 to 102 cm, women 80 to 88 cm (3p); men>102 cm women> 88 cm (4p).

*Do you usually have daily at least 30 minutes of physical activity at work and/or during leisure time (including normal daily activity)?* No (0p); Yes (2p). Physical activity (PA) in this survey was estimated using questions developed by the Swedish National Board of Health and Welfare (TNBHW) to estimate time spent physically active [16]: Time spending non-strenuous PA (e.g., walking, cycling, or gardening), or undertaking strenuous PA (e.g., jogging, swimming, basketball, or football) was estimated by the participants in minutes. Time conducting strenuous PA was multiplied by two and then summed with time spent doing non-strenuous PA [16]. Total minutes per week were then dichotomized into more, or less than PA 30 minutes per day.

*How often do you eat vegetables, fruit or berries?* Every day (0p), Not every day (1p).

*Have you ever taken medication for high blood pressure on regular basis?* No (0p); Yes (2p).

Medication for high blood pressure included participants with medication with beta blockers,

calcium channel blockers, angiotensin-converting-enzyme inhibitors, angiotensin II receptor antagonists, diuretics.

*Have you ever been found to have high blood glucose (e.g., in a health examination, during an illness or during pregnancy). No (0p); Yes (5p).*

*Have any of the members of your immediate family or other relatives been diagnosed with diabetes (type 1 or type 2)? No (0p); Yes: grandparent, aunt, uncle and/or cousin (3p); Yes: parent, brother, sister or own child (5p).*

### *Statistical analysis*

Analyses were performed using STATA IC/12.1. Least squares means were derived after age and sex adjustment using linear regression, whereas differences in proportions were adjusted for age and sex using logistic regression. Associations with T2D diabetes were estimated using multivariate logistic regression expressed as odds ratios (ORs) with 95% confidence intervals (95% CIs). Odds ratios (OR) were standardized (SD OR) per 1 SD unit variance for the independent variables. Standardizations were done in the strata of ethnicity and sex. All tests were two-sided and a  $p$ -value of  $<0.05$  was considered statistically significant. Multicollinearity was tested for but was not considered an issue since all variance inflation factors (VIP) in the multivariate regression model had values  $<3.9$ .

## Results

### *Basic characteristics of the study population, Table 1*

In total, 1398 residents born in Iraq and 757 residents born in Sweden participated in this study. Although Iraqis were younger, twice as many were diagnosed with diabetes (new and previously diagnosed cases) (11.6 vs. 5.8%,  $p<0.001$ ) and diabetes onset occurred on average six years earlier compared to Swedes. According to the prevalence of FINDRISC variables, Iraqis were worse off in almost all aspects with higher prevalence of abdominal obesity, overweight and obesity, family history of diabetes and physical inactivity.

### *Odds of diabetes and diabetes risk estimation, based on FINDRISC scores*

We studied the odds of T2D diabetes according to FINDRISC risk factors, but also included ethnicity as a risk factor. In this model, participants with larger waist circumference, family history of diabetes and/or hypertensive medication, independently of the influence of other risk factors had increased odds of T2D. In addition we also observed that the odds of T2D in participants born in Iraq were almost as high as in participants with a family history of diabetes. Within this survey ethnic background did not act as an effect modifier on the outcome of our data.

Participants without diabetes were categorized at “low”, “slightly elevated”, “moderate”, “high” and at “very high” risk for diabetes according to FINDRISC criteria, including participants with IGT or IGR in the very high risk group. Only 17.6% of Iraqi participants versus 33.4% of Swedish participants were at “low risk” for diabetes whereas a higher proportion of Iraqis were at “moderate” to “very high risk” of diabetes as compared to Swedes (Figure 2). Based on FINDRISC estimates of diabetes incidence the forthcoming decade [10], we assessed diabetes

incidence from the distribution of participants in each risk group (Figure 2). Our data revealed a higher proportion of the Iraqi than the Swedish born participants that were estimated to develop diabetes within the next ten years (16.2 vs. 12.3%,  $p<0.001$ , age and sex adjusted data).

#### *Estimation of health related costs the coming decade in immigrants from Iraq to Sweden*

Out of 125 000 Iraqi born individuals in Sweden in (2012), 73 000 were 30 to 75 years of age and within the same age groups as in this survey [17]. Based on our results, approximately 11.6% or 8 500 of the adult Iraqi population 30 to 75 years of age had T2D and of those that had not yet developed diabetes (64 500), we estimate that 16.2% or 10 500 will develop diabetes within the next decade. Thus 19 000 of the Iraqi population in Sweden are estimated to be diagnosed with diabetes in 2023 provided they are all still alive by then. Considering that a previous study from 2005 in Sweden have shown that for each individual that develop diabetes, the total annual cost (including healthcare costs, productivity loss, lost life-years and lost productivity years) is approximately EUR 3700 [8], we estimate that the total annual cost for diabetes in the Iraqi population will account for at least 7 mEUR. If the Iraqi population would have had a prevalence and incidence of diabetes within the level of the Swedish population 12 750 Iraqis are estimated to have diabetes in 10 years accounting for a total annual cost of 4.7 mEUR. This would equal a saved annual diabetes related cost for the Swedish society of 2.3 mEUR.

#### *Representativeness of the study sample*

The participants in this study were somewhat older compared to the eligible background population (Iraqis by 1.7 years, 95% CI 0.9-2.5,  $p<0.001$ ; Swedes by 4.5 years, 95% CI 3.5-5.6,

$p < 0.001$ ), but the prevalence of self-reported T2D in participants versus non-participants did not differ significantly (data not shown).

## Discussion

### *Key findings*

Our study suggests that Middle Eastern ethnicity should be considered an independent risk factor for T2D and in a clinical setting they should be tested for T2D on wide indications. Further our study suggests that the high proportion of immigrants from the Middle East that have or are estimated to soon develop T2D will generate substantial diabetes related costs for healthcare, productivity loss, lost life-years, lost productivity years not accounting for the effect on quality of life. There is an urge for culturally adopted intensive preventive actions in a clinical but also societal level targeting this high risk group, representing a large proportion of the Swedish population.

### *Population at risk for diabetes*

To the best of our knowledge this is the first study to report estimates of diabetes incidence rates in immigrants from the Middle East that represent a high risk group of diabetes [18]. The high prevalence of T2D among the relatively young ethnic Iraqis in our study (11.6%) is higher than figures reported from Iraq in 2010 (7.8%) [19] which is in consistency with other studies reporting that migration per se increases the risk of developing T2D [5]. Our study also shows that the prevalence of T2D in ethnic Swedes has doubled since 1987 (from 3.3 to 5.8%) [20], which is also in consistency with recent reports of an increasing prevalence of diabetes globally that in Sweden is estimated to reach 8% in 2030 [19]. We consider Iraqi ethnicity, in the perspective of T2D prevalence, to be representative of Middle Eastern populations, as previous studies have reported similar prevalences of T2D in immigrants from the Middle East to



Northern Europe with risk estimates compared to natives ranging from OR=1.7 to 5.5 depending on setting and age-group studied [18]. This is consistent with our results (OR=2.5, 95% CI 1.6 to 3.9).

The estimated incidence rate of T2D in immigrants from Iraq in this survey is higher than in Swedes, but the actual incidence rate may be higher still. The early diabetes onset and worse metabolic control, as indicated by the high prevalence of Iraqi participants with overweight, abdominal obesity, family history of diabetes and physical inactivity, may result in a higher future risk of diabetic complications and early death. This supposition is supported by previous studies reporting that patients with early T2D onset progress to diabetic complication at a faster pace and have a shorter life expectancy than their older counterparts [21] and is also consistent with studies of patients with diabetes showing worse metabolic control in Middle Eastern immigrants to Sweden compared with non-immigrants [22]. Further, others have reported a high prevalence of micro- and macro vascular complications already in the pre-diabetic stages in Arabic populations [23].

Another factor that may influence the incidence rate is that recent studies have reported that immigrants from non-westernized countries to Sweden receive worse preventive health care and that they to a lower extent retrieve the preventive medication they are prescribed against chronic diseases such as diabetes and cardiovascular disease [24].

We also consider the actual costs to be considerably higher than the estimates used in this survey because the costs generated in the primary health care, where most T2D patients are cared for, were not included in the analysis by Bolin et al. [8]. In addition, that survey presented estimates for 2005 and the costs have most probably increased since then.

### *Screening for diabetes*

Our results altogether show that there is a substantial incitement for intensive preventive actions highlights a target population for intervention and screening in this high risk group, representing a large proportion of the immigrant Swedish population. Active screening for T2D combined with subsequent lifestyle intervention is cost-effective compared to the “wait and see” approach [25] that currently prevails in the Swedish society and health care of today. FINDRISC scores can be easily applied in a clinical setting for identification of individuals at high risk for diabetes. However, our data implies that Middle Eastern ethnicity per se is a risk factor for diabetes that is independent of overweight, diabetes family history or lifestyle factors. The reason for this is unclear but may be a consequence of metabolic differences affecting glucose metabolism not captured in the FINDRISC model. Our study further suggests that FINDRISC underestimates diabetes risk in immigrants from the Middle East; hence when estimating diabetes risk ethnic background should be taken into consideration. Considering that half of those with diabetes are undiagnosed [26] our data suggests that in a clinical setting, patients with Middle Eastern ethnicity should be tested for diabetes on broader indications than for lower risk ethnic groups, such as ethnic Swedes.

Randomized controlled trials have demonstrated that T2D can be delayed by preventive lifestyle interventions and that changes in lifestyle can reduce the risk of developing T2D substantially [27]. However, as proposed previously the use of risk scores in high risk populations to target public health interventions are sparse [9] and it is crucial that these interventions are culturally adopted since there are several obstacles and issues that need to be addressed in order to achieve successful lifestyle change in immigrants from the Middle East [28, 29].

### *Strengths and limitations*

The major strengths of this study are that it is set in Sweden, where healthcare, education, and employment are equally accessible to immigrant and non-immigrant populations. Thus, confounding and bias attributable to these factors are likely to be less than in other study settings. Our study is also population-based and represents a large fraction of the Iraqi population within the studied region. The study is also distinct from other studies of this topic in that it includes detailed metabolic phenotyping and assessments of lifestyle exposures.

The age distribution in Iraqi and Swedish participants differed in the present study. However, because the Iraqi participants were younger than the Swedish participants, and older age is a risk factor for diabetes, it is unlikely that this age difference positively confounded the associations reported here.

The study is limited by the participation of more Iraqi men than women, which may reflect attitudes towards scientific research and other gender-specific sociocultural factors. Another limitation is the cross-sectional design making it difficult to draw conclusions regarding the order of causality in relation to T2D.

### *Conclusions*

Our study suggests that Middle Eastern ethnicity in a clinical setting should be considered an independent risk factor for diabetes when estimating diabetes risk. The high proportion of ethnic Iraqis who have diabetes and are estimated to develop diabetes within the next decade will generate substantial diabetes-related costs owing to increased healthcare costs as well as productivity loss. An epidemic of this nature will also diminish the quality and duration of life in this population. Thus, culturally adapted intensive prevention strategies targeting this high risk

group which represents a large proportion of the Swedish population, may be warranted.

#### Acknowledgements

We are indebted to: Marita Olsson, Katarina Balcker Lundgren, Enas Basheer El-Soussi, Asma Saleh and Adel Gahne for their excellent work in examining the participants and collecting data.

#### Funding

Government Grant for Clinical Research (“ALF”) and Region Skåne Strategic Research funds.

#### Duality of interest

There are no conflicts of interests.

#### Contribution statement


L.B. wrote the manuscript, obtained, analyzed and interpreted the data. L.G. contributed to interpretation of the data and discussions. U.L. contributed to interpretation of the data and discussions. C-D.A, contributed to interpretation of the data, discussions and in writing the manuscript. P.W.F contributed to interpretation of the data, discussions and in writing the manuscript. All authors have revised/edited the article critically and have approved the final version of the manuscript.

## References

1. Unwin N, Shaw J, Zimmet P, Alberti KG: **Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention.** *Diabet Med* 2002, **19**(9):708-723.
2. Zimmet P, Magliano D, Matsuzawa Y, Alberti G, Shaw J: **The metabolic syndrome: a global public health problem and a new definition.** *J Atheroscler Thromb* 2005, **12**(6):295-300.
3. Glans F, Elgzyri T, Shaat N, Lindholm E, Apelqvist J, Groop L: **Immigrants from the Middle-East have a different form of Type 2 diabetes compared with Swedish patients.** *Diabet Med* 2008, **25**(3):303-307.
4. Mansour AA, Wanoose HL, Hani I, Abed-Alzahrea A: **Diabetes screening in Basrah, Iraq: a population-based cross-sectional study.** *Diabetes Res Clin Pract* 2008, **79**(1):147-150.
5. Wandell PE, Carlsson A, Steiner KH: **Prevalence of diabetes among immigrants in the Nordic countries.** *Curr Diabetes Rev* 2010, **6**(2):126-133.
6. Wandell PE, Wajngot A, de Faire U, Hellenius ML: **Increased prevalence of diabetes among immigrants from non-European countries in 60-year-old men and women in Sweden.** *Diabetes Metab* 2007, **33**(1):30-36.
7. Wändell PE: **Quality of life of patients with diabetes mellitus. An overview of research in primary health care in the Nordic countries.** *Scand J Prim Health Care* 2005, **23**(2):68-74.
8. Bolin K, Gip C, Mörk AC, Lindgren B: **Diabetes, healthcare cost and loss of productivity in Sweden 1987 and 2005--a register-based approach.** *Diabet Med* 2009, **26**(9):928-934.
9. Noble D, Mathur R, Dent T, Meads C, Greenhalgh T: **Risk models and scores for type 2 diabetes: systematic review.** *BMJ* 2011, **343**:d7163.
10. Lindström J, Tuomilehto J: **The diabetes risk score: a practical tool to predict type 2 diabetes risk.** *Diabetes Care* 2003, **26**(3):725-731.
11. WMA: **Declaration of Helsinki - Ethical principles of medical research involving human subjects.** 2008:<http://www.wma.net/en/30publications/10policies/b33/index.html>.
12. Bennet L, Johansson SE, Agardh CD, Groop L, Sundquist J, Rastam L, Sundquist K: **High prevalence of type 2 diabetes in Iraqi and Swedish residents in a deprived Swedish neighbourhood - a population based study.** *BMC public health* 2011, **11**(1):303.
13. **World Health Organization; Definition, diagnosis and classification of diabetes mellitus and its complications: Report of a WHO consultation. Part 1. Diagnosis and classification of diabetes mellitus.** In. Geneva, World Health Organization; 1999.
14. Shaw JE, Zimmet PZ, de Courten M, Dowse GK, Chitson P, Gareeboo H, Hemraj F, Fareed D, Tuomilehto J, Alberti KG: **Impaired fasting glucose or impaired glucose tolerance. What best predicts future diabetes in Mauritius?** *Diabetes Care* 1999, **22**(3):399-402.
15. Stern MP, Williams K, Haffner SM: **Identification of persons at high risk for type 2 diabetes mellitus: do we need the oral glucose tolerance test?** *Ann Intern Med* 2002, **136**(8):575-581.
16. **Nationella riktlinjer för sjukdomsförebyggande behandling** [<http://www.socialstyrelsen.se/publikationer2011/2011-11-11>]
17. **Statistics Sweden.** Available at <http://www.scb.se>. In.: Statistics Sweden.
18. Wandell PE, Johansson SE, Gafvels C, Hellenius ML, de Faire U, Sundquist J: **Estimation of diabetes prevalence among immigrants from the Middle East in Sweden by using three different data sources.** *Diabetes Metab* 2008, **34**(4 Pt 1):328-333.
19. Shaw JE, Sicree RA, Zimmet PZ: **Global estimates of the prevalence of diabetes for 2010 and 2030.** *Diabetes Res Clin Pract* 2010, **87**(1):4-14.
20. Falkenberg MG: **Diabetes mellitus: prevalence and local risk factors in a primary health care district.** *Scand J Soc Med* 1987, **15**(3):139-144.


21. Rhodes ET, Prosser LA, Hoerger TJ, Lieu T, Ludwig DS, Laffel LM: **Estimated morbidity and mortality in adolescents and young adults diagnosed with Type 2 diabetes mellitus.** *Diabet Med* 2012, **29**(4):453-463.
22. Sundquist K, Chaikiat A, León VR, Johansson SE, Sundquist J: **Country of birth, socioeconomic factors, and risk factor control in patients with type 2 diabetes: a Swedish study from 25 primary health-care centres.** *Diabetes Metab Res Rev* 2011, **27**(3):244-254.
23. Saadi H, Carruthers SG, Nagelkerke N, Al-Maskari F, Afandi B, Reed R, Lukic M, Nicholls MG, Kazam E, Algawi K *et al*: **Prevalence of diabetes mellitus and its complications in a population-based sample in Al Ain, United Arab Emirates.** *Diabetes Res Clin Pract* 2007, **78**(3):369-377.
24. Eriksson T: **Empirical Essays of Health and Human Capital.** Lund University; 2013.
25. Hoerger TJ, Hicks KA, Sorensen SW, Herman WH, Ratner RE, Ackermann RT, Zhang P, Engelgau MM: **Cost-effectiveness of screening for pre-diabetes among overweight and obese U.S. adults.** *Diabetes Care* 2007, **30**(11):2874-2879.
26. **IDF Diabetes Atlas, Undiagnosed diabetes.** [<http://www.idf.org/diabetesatlas/5e/undiagnosed-diabetes>]
27. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M *et al*: **Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance.** *N Engl J Med* 2001, **344**(18):1343-1350.
28. Lirussi F: **The global challenge of type 2 diabetes and the strategies for response in ethnic minority groups.** *Diabetes Metab Res Rev* 2010, **26**(6):421-432.
29. Saha S, Leijon M, Gerdtham U, Sundquist K, Sundquist J, Arvidsson D, Bennet L: **A culturally adapted lifestyle intervention addressing a Middle Eastern immigrant population at risk of diabetes, the MEDIM (impact of Migration and Ethnicity on Diabetes In Malmo): study protocol for a randomized controlled trial.** *Trials* 2013, **14**(1):279.

**Figure 1.** Flow diagram of the recruitment of the study population. PR, participation rate.



**Figure 2.** Distribution of Iraqi and Swedish participants without diabetes in relation to low, slightly elevated, moderate, high risk and very high risk of diabetes according to FINDRISC criteria. Participants with IGT or IGR were considered being at very high risk irrespective of other risk factors.

Comparisons between Iraqi and Swedish participants were age and sex adjusted.





**Table 1.** Characteristics of residents of Malmö born in Iraq and Sweden according to FINDRISC risk factors for type 2 diabetes.

|   | Iraq<br><i>N</i> = 1398 | Sweden<br><i>N</i> =757 | <i>p</i> |
|---|-------------------------|-------------------------|----------|
| Age, years  | 46.2 (9.6)              | 49.5 (11.2)             | <0.001   |
| Male sex, <i>n</i> (%)  | 819 (58.6)              | 378 (49.9)              | 0.010    |
| Type 2 diabetes, new and previously diagnosed cases, <i>n</i> (%)         | 162 (11.6)              | 44 (5.8)                | <0.001   |
| Age at diabetes onset (years)   | 47.6 (9.9)              | 53.8 (13.0)             | 0.001    |
| Age categories, years, <i>n</i> (%)                                       |                         |                         |          |
| <45   | 682 (48.8)              | 278 (36.7)              | <0.001   |
| 45–54   | 466 (33.3)              | 225 (29.7)              | 0.087    |
| 55–64   | 193 (13.8)              | 166 (21.9)              | <0.001   |
| >64   | 57 (4.1)                | 88 (11.6)               | <0.001   |
| Body mass index, kg/m <sup>2</sup>  | 29.3 (4.5)              | 27.3 (4.7)              | <0.001   |
| Body mass index, kg/m <sup>2</sup> , <i>n</i> (%)                         |                         |                         |          |
| <25.0   | 200 (14.3)              | 269 (35.5)              | <0.001   |
| 25.0–29.9   | 674 (48.2)              | 314 (41.5)              | 0.005    |
| ≥30.0   | 524 (37.5)              | 174 (23.0)              | <0.001   |
| Waist circumference, men (cm)   | 99.3 (10.6)             | 93.1 (10.9)             | 0.002    |
| Waist circumference, women (cm)   | 97.8 (11.7)             | 89.2 (14.1)             | <0.001   |
| Waist, cm (men; women), <i>n</i> (%)                                      |                         |                         |          |
| <94; <80  | 314 (22.5)              | 247 (32.6)              | <0.001   |
| 94–102; 80–88   | 410 (29.3)              | 219 (28.9)              | <0.001   |
| >102; >88   | 674 (48.2)              | 291 (38.4)              | <0.001   |
| History of high glucose levels, <i>n</i> (%)                              | 14 (1.0)                | 1 (0.1)                 | 0.033    |
| Physical activity <30 min/day, <i>n</i> (%)                               | 1005 (71.9)             | 292 (38.6)              | <0.001   |
| Intake of vegetables, fruit or berries, less than every day, <i>n</i> (%) | 715 (51.1)              | 373 (49.3)              | 0.803    |
| Antihypertensive medication, <i>n</i> (%)                                 | 176 (12.6)              | 115 (15.2)              | 0.151    |
| Family history of diabetes, <i>n</i> (%)                                  |                         |                         |          |
| No family history   | 659 (47.1)              | 489 (64.6)              | <0.001   |
| Second degree history   | 16 (1.1)                | 59 (7.8)                | <0.001   |
| First degree history  | 723 (51.7)              | 209 (27.6)              | <0.001   |

**Table 2.** The odds of type 2 diabetes in participants born in Iraq or Sweden according to FINDRISC factors, associations expressed as odds ratios (OR) with 95% confidence intervals (CIs). Significant values are bolded.

|  | Univariate data |             |             | Multivariate adjusted data<br>N=1955 |             |             |
|--|-----------------|-------------|-------------|--------------------------------------|-------------|-------------|
| Risk factors in accordance with FINDRISC       | OR              | 95% CI      |             | OR                                   | 95% CI      |             |
| Born in Iraq                                   | <b>2.12</b>     | <b>1.50</b> | <b>2.99</b> | <b>2.52</b>                          | <b>1.64</b> | <b>3.87</b> |
| Age (years)                                    | <b>1.08</b>     | <b>1.06</b> | <b>1.09</b> | <b>1.11</b>                          | <b>1.04</b> | <b>1.08</b> |
| Male sex                                       | <b>1.44</b>     | <b>1.07</b> | <b>1.95</b> | 0.86                                 | 0.57        | 1.30        |
| BMI (kg/m <sup>2</sup> )                       | <b>1.13</b>     | <b>1.10</b> | <b>1.16</b> | 0.99                                 | 0.93        | 1.06        |
| Waist circumference (cm)                       | <b>1.07</b>     | <b>1.06</b> | <b>1.08</b> | <b>1.06</b>                          | <b>1.03</b> | <b>1.09</b> |
| First degree family history of type 2 diabetes | <b>2.32</b>     | <b>1.71</b> | <b>3.13</b> | <b>1.82</b>                          | <b>1.28</b> | <b>2.58</b> |
| Antihypertensive medication                    | <b>6.27</b>     | <b>4.57</b> | <b>8.59</b> | <b>3.45</b>                          | <b>2.38</b> | <b>5.00</b> |
| Physical activity <30 min per day              | 1.15            | 0.86        | 1.55        | 1.03                                 | 0.72        | 1.47        |
| Intake of fruit/vegetables less than daily     | 1.01            | 0.76        | 1.35        | 1.04                                 | 0.74        | 1.45        |

Data was analyzed using univariate and multivariate logistic regression. Neither history of high glucose levels, nor second degree family history of diabetes was included in the analysis because of few cases. Multicollinearity VIF<3.9.